Evaluation of Serum Chemokines for Patients Undergoing Treatment With Boceprevir.

University of North Carolina (UNC)

Status: Withdrawn

Conditions: Hepatitis C

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT01949077

11-2124

Details and patient eligibility

About

The purpose of the study is to determine differences in levels of serum chemokines from patients undergoing treatment with Boceprevir. The aim is to determine if non-responders have significantly different levels of chemokines than responders.

Full description

Patients undergoing standard of care at the UNC Liver Center are consented for collection of an additional serum sample under the UNC Liver Center serum and tissue bank study. These samples will be used to analyze differences in serum chemokines across responders and non-responders.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• All adult patients (age 18 or older) treated with an antiviral Hepatitis C treatment regimen that includes Boceprevir.

Exclusion criteria

• Inability to provide informed consent for a serum sample enrolled in the University of North Carolina Liver Center serum bank.
• No pre and post serum sample available within 6 months of the treatment period.

Trial design

0 participants in 2 patient groups

Sustained virological response

Description:

Patients who achieve sustained virological response (SVR) are defined as undetectable HCV RNA in serum obtained 12 weeks or beyond the end of antiviral therapy.

Non-responders

Description:

Non-responders are defined as patients who have not achieved virological milestones during therapy or who have relapsed with detectable HCV RNA in serum after cessation of treatment.